Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MicuRx Pharmaceuticals

This article was originally published in Start Up

Executive Summary

Like numerous other companies working to develop novel anti-bacterial drugs, MicuRx Pharmaceuticals Inc. aims to modify existing chemical scaffolds to come up with better compounds. The start-up is particularly interested in four scaffolds known to inhibit protein synthesis-a common mechanism of action for anti-bacterial drugs. While the company's CEO and CSO-both of whom were among the scientific founders of Vicuron Pharmaceuticals--can offer much from their personal experience, MicuRx is carefully mining medical literature for insights and observations that can inform specific modifications to drug molecules.
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091520

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel